Mike joined Ardelyx as Executive Vice President of Corporate Development and Strategy in March 2024. Mike brings more than 20 years of experience in corporate strategy, mergers and acquisitions, strategic partnerships and licensing from leading biotechnology and global pharmaceutical companies.
Prior to Ardelyx, Mike served as group vice President, M&A and Business Development, at Horizon Therapeutics, a global biotechnology company focused on researching, developing, and commercializing medicines for rare, autoimmune, and severe inflammatory diseases. Mike joined Horizon in 2014 and held roles of increasing responsibility on the team that led an aggressive growth and expansion agenda through acquisitions, development collaborations, and other transactions, including the acquisition of Horizon by Amgen. Mike was instrumental in transforming Horizon into a $28 billion, innovation-driven biotech company. Prior to his time at Horizon, from 2009 to 2014, Mike held financial roles at Elan Corporation (now Perrigo Company), a leading global pharmaceutical company, where he oversaw strategic partnerships and collaborations, and advised its Board of Directors and senior leadership on investments, business development, product commercialization, and asset monetization.
Mike began his career in banking, public accounting, and corporate finance and earned a Bachelor of Commerce from the University College Cork (Ireland). He is also an Associated Chartered Accountant.
What is Mike Kelliher's net worth?
The estimated net worth of Mike Kelliher is at least $1.61 million as of November 21st, 2025. Kelliher owns 271,181 shares of Ardelyx stock worth more than $1,605,392 as of December 5th. This net worth approximation does not reflect any other assets that Kelliher may own. Learn More about Mike Kelliher's net worth.
How old is Mike Kelliher?
Kelliher is currently 47 years old. There are 6 older executives and no younger executives at Ardelyx. The oldest executive at Ardelyx is Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer, who is 64 years old. Learn More on Mike Kelliher's age.
How do I contact Mike Kelliher?
Has Mike Kelliher been buying or selling shares of Ardelyx?
During the past quarter, Mike Kelliher has sold $30,802.40 in shares of Ardelyx stock. Most recently, Mike Kelliher sold 5,560 shares of the business's stock in a transaction on Friday, November 21st. The shares were sold at an average price of $5.54, for a transaction totalling $30,802.40. Following the completion of the sale, the insider now directly owns 271,181 shares of the company's stock, valued at $1,502,342.74. Learn More on Mike Kelliher's trading history.
Who are Ardelyx's active insiders?
Ardelyx's insider roster includes Robert Blanks (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 7 times. They purchased a total of 1,371,406 shares worth more than $5,780,176.94. In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 580,304 shares worth more than $3,050,503.57. The most recent insider tranaction occured on November, 21st when insider Elizabeth A Grammer sold 5,995 shares worth more than $33,212.30. Insiders at Ardelyx own 4.8% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 11/21/2025.
